Gaithersburg, Maryland’s Novavax has skyrocketed to national and global prominence during the coronavirus pandemic. In an incredibly short time, the company has advanced its SARS-CoV-2 vaccine candidate into Phase III trials and received FDA fast track designation, putting its vaccine very close to potential FDA approval.
This year, more than ever before, we’ve seen just how important it is for us all to stay connected and work together to build a stronger biotech ecosystem. In the face of great adversity, the biotech community has risen to the challenge and formed new collaborations and partnerships to innovate and rapidly develop new medicines and tools to help us beat this pandemic.
Global COVID-19 cases have been spiking in Europe and the U.S. as the predicted second wave is hitting communities hard, applying new pressure on hospital capacity and forcing local and state governments to once again tighten restrictions.
Over the past nine months, more than $7 billion in federal funding has poured into the BioHealth Capital Region aimed at the battle against COVID-19 and has shown a spotlight on the broad impact biopharma life science companies and academic institutions are making in the fight against the pandemic.
Over the past nine months, more than $7 billion in federal money has poured into the BioHealth Capital Region in support of therapies, diagnostics, and vaccines against COVID-19. In that short time, the region has shown its importance in halting the spread of the ongoing pandemic.
The state of Maryland is the global epicenter of vaccine research and development. This has never been more evident than right now as scores of Maryland companies have risen to the global challenge of developing the first approved vaccine for SARS-CoV-2.
Top Seven Biotech Stock Gains in 2020 Linked to COVID-19
Novovax announced that Silvia Taylor, MBA, has joined the company as SVP, Investor Relations, and Corporate Affairs GAITHERSBURG, Md., June 17, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing [….]
Novavax Appoints Biotechnology Veteran David Mott to Board of Directors GAITHERSBURG, Md., June 16, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today [….]
COVID-19 Vaccine Progress from 14 BioHealth Capital Region Companies
